By Fineline Cube 
Insilico Medicine (HKG: 3696) has signed a tripartite strategic cooperation agreement with Byterna Therapeutics, a biopharmaceutical company specializing in next-generation intelligent R&D of in vivo RNA therapies including in vivo CAR-T, and DuneQ, a frontier technology enterprise developing the next-generation peptide drug design platform (HQL) that integrates quantum computing and AI. The collaboration aims to leverage quantum computing advantages to enhance generative AI capabilities and accelerate the development of novel therapeutic modalities across RNA, peptide, and cell therapy platforms.
Partnership Structure & Strategic Investments
| Component | Detail |
|---|---|
| Lead Partner | Insilico Medicine (HKG: 3696) |
| Biotech Partner | Byterna Therapeutics (in vivo RNA therapies, in vivo CAR-T) |
| Technology Partner | DuneQ (quantum computing + AI peptide platform) |
| Investment Component | Insilico participated as strategic investor in Byterna’s Pre-A round (tens of millions RMB) |
| Funding Purpose | Clinical advancement of in vivo CAR-T and cancer vaccine pipelines; joint AI-native mRNA R&D engine |
| Announcement Date | July 21, 2026 |
Technology Integration Framework
- Insilico Medicine Contribution: Full deployment of proprietary end-to-end generative AI platform, Pharma.AI
- DuneQ Contribution: Computational power support and high-precision synthetic data from Heterogeneous Quantum Physics Engine (HQL)
- Byterna Contribution: Innovative application scenarios including:
- Circular mRNA sequence design
- In vivo lipid nanoparticle delivery systems (tLNP)
- Personalized cancer vaccine design
- Validation Objective: Demonstrate feasibility and performance advantages of “Quantum + AI” closed-loop system in real-world drug discovery applications
Strategic Rationale & Innovation Pipeline
- Novel Modality Focus: Addresses emerging therapeutic categories including in vivo CAR-T, mRNA vaccines, and quantum-designed peptides
- Technology Synergy: Combines generative AI’s pattern recognition with quantum computing’s computational precision for complex biological problems
- Platform Scalability: Creates reusable infrastructure for multiple therapeutic modalities beyond initial focus areas
- Competitive Differentiation: First-of-its-kind integration of quantum computing specifically optimized for biopharmaceutical R&D
- Speed-to-Clinic: Aims to compress traditional drug discovery timelines through enhanced computational prediction accuracy
Market Context & Industry Implications
- AI Drug Discovery Evolution: Represents next-generation convergence of multiple advanced technologies beyond standard machine learning
- Quantum Computing Applications: Demonstrates practical near-term applications of quantum computing in life sciences
- In Vivo Cell Therapy: Addresses technical challenges in delivering cell therapies without ex vivo manufacturing complexity
- Personalized Medicine: Enables rapid design and optimization of patient-specific therapeutic candidates
- Investment Validation: Strategic investment by Insilico signals confidence in Byterna’s technology platform and clinical potential
The tripartite alliance positions the partners at the forefront of computational drug discovery, creating a unique ecosystem that combines cutting-edge AI, quantum computing, and innovative therapeutic modalities to address previously intractable drug development challenges.
Forward-Looking Statements
This brief contains forward-looking statements regarding technology integration, partnership outcomes, and development timelines. Actual results may differ due to technical feasibility, regulatory requirements, and market dynamics.-Fineline Info & Tech